177 related articles for article (PubMed ID: 35567723)
1. Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production.
Sun Y; Huang L; Nie J; Feng K; Liu Y; Bai Z
AMB Express; 2022 May; 12(1):58. PubMed ID: 35567723
[TBL] [Abstract][Full Text] [Related]
2. The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process.
Nie J; Sun Y; Feng K; Huang L; Li Y; Bai Z
Vaccine; 2022 Mar; 40(13):2036-2043. PubMed ID: 35216843
[TBL] [Abstract][Full Text] [Related]
3. Optimization of an adenovirus-vectored zoster vaccine production process with chemically defined medium and a perfusion system.
Nie J; Sun Y; Ren H; Huang L; Feng K; Li Y; Bai Z
Biotechnol Lett; 2022 Nov; 44(11):1347-1358. PubMed ID: 36183022
[TBL] [Abstract][Full Text] [Related]
4. Application of Multivariate Data Analysis on Historical Recombinant Adenovirus Zoster Vaccine Production Data for Upstream Process Improvements.
Nie J; Ren H; Sun Y; Li Y; Zhang Y; Bai Z
J Pharm Sci; 2024 May; 113(5):1168-1176. PubMed ID: 38447668
[TBL] [Abstract][Full Text] [Related]
5. Rapid process development of serum-free pseudorabies virus production with the Quality by Design approach.
Nie J; Sun Y; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
Cytotechnology; 2020 Apr; 72(2):283-293. PubMed ID: 32086694
[TBL] [Abstract][Full Text] [Related]
6. Culture media optimization for Chinese hamster ovary cell growth and expression of recombinant varicella-zoster virus glycoprotein E.
Kim KS; Park SA; Wui SR; Ko A; Lee NG
Cytotechnology; 2021 Jun; 73(3):433-445. PubMed ID: 33897103
[TBL] [Abstract][Full Text] [Related]
7. [Hyperosmotic stress and perfusion culture strategies increase the yield of recombinant adenoviral vector produced by HEK 293 cells].
Zhang Z; Bai Z; Liu G; Nie J; Yang Y
Sheng Wu Gong Cheng Xue Bao; 2023 Aug; 39(8):3364-3378. PubMed ID: 37622366
[TBL] [Abstract][Full Text] [Related]
8. Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain?
Harbecke R; Jensen NJ; Depledge DP; Johnson GR; Ashbaugh ME; Schmid DS; Breuer J; Levin MJ; Oxman MN
Vaccine; 2020 Jan; 38(2):150-157. PubMed ID: 31679866
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
[TBL] [Abstract][Full Text] [Related]
10. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
[TBL] [Abstract][Full Text] [Related]
11. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
[TBL] [Abstract][Full Text] [Related]
13. Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature.
Wang L; Verschuuren EAM; van Leer-Buter CC; Bakker SJL; de Joode AAE; Westra J; Bos NA
Front Immunol; 2018; 9():1632. PubMed ID: 30079064
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
[TBL] [Abstract][Full Text] [Related]
15. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD008858. PubMed ID: 26937872
[TBL] [Abstract][Full Text] [Related]
16. Pediatric vaccine-strain herpes zoster: a case series.
Dreyer S; Hemarajata P; Hogeling M; Henderson GP
Pediatr Dermatol; 2017 Nov; 34(6):665-667. PubMed ID: 28944968
[TBL] [Abstract][Full Text] [Related]
17. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity.
Liesegang TJ
Ophthalmology; 2008 Feb; 115(2 Suppl):S3-12. PubMed ID: 18243930
[TBL] [Abstract][Full Text] [Related]
18. Herpes zoster virus vaccine.
Woolery WA
Geriatrics; 2008 Oct; 63(10):6-9. PubMed ID: 18828650
[TBL] [Abstract][Full Text] [Related]
19. Human amniocyte-derived cells are a promising cell host for adenoviral vector production under serum-free conditions.
Silva AC; Simão D; Küppers C; Lucas T; Sousa MF; Cruz P; Carrondo MJ; Kochanek S; Alves PM
Biotechnol J; 2015 May; 10(5):760-71. PubMed ID: 25943527
[TBL] [Abstract][Full Text] [Related]
20. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
